Idiopathic gastroparesis

disease
On this page

Summary

Idiopathic gastroparesis (MONDO:0034150) is a disease and 15 clinical trials. Top therapeutic interventions include nortriptyline hydrochloride, olanzapine, and tradipitant. A subtype of gastroparesis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-5 / 10 000 (Specific population) [Orphanet-validated]
  • Clinical trials: 15

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-5 / 10 00011.4Specific populationValidated

Identifiers

Disease identifiers

FieldValue
Canonical nameidiopathic gastroparesis
Mondo IDMONDO:0034150
Orphanet558411
UMLSC0267171
MedGen540450
GARD0022249
Is cancer (heuristic)no

Disease family

This is a subtype of gastroparesis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderstomach disorderfunctional gastric diseasegastroparesisidiopathic gastroparesis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified7
PHASE24
PHASE33
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06836557PHASE3RECRUITINGOpen Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
NCT00765895PHASE3COMPLETEDNortriptyline for Idiopathic Gastroparesis
NCT04028492PHASE3COMPLETEDEvaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
NCT06899217PHASE2ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
NCT03281577PHASE2COMPLETEDEffect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
NCT03544229PHASE2COMPLETEDA Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
NCT04303195PHASE2COMPLETEDA Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
NCT03176927EARLY_PHASE1COMPLETEDBiomagnetic Characterization of Gastric Dysrhythmias III
NCT01793168Not specifiedRECRUITINGRare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT01625923Not specifiedTERMINATEDA Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis
NCT01696747Not specifiedCOMPLETEDGastroparesis Registry 2
NCT01916460Not specifiedCOMPLETEDIntraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients
NCT02232334Not specifiedUNKNOWNEffects of Global Osteopathic Manual Treatments in Patients With Idiopathic Gastroparesis
NCT02732821Not specifiedCOMPLETEDG-POEM for Treatment of Refractory Gastroparesis
NCT03680859Not specifiedCOMPLETEDGastroparesis Registry 3

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
NORTRIPTYLINE HYDROCHLORIDE41
OLANZAPINE41
TRADIPITANT32
FELCISETRAG21
TRAZPIROBEN21